Age-Related Macular Degeneration: What Your Diagnosis Means and What to Do Next

Age-related macular degeneration (ARMD) is one of the leading causes of irreversible central vision loss in adults over 50 in the United States.¹ The macula — the small central region of the retina responsible for reading, facial recognition, and fine detail — deteriorates gradually, often silently before any symptoms appear.

Your Annual Exam Is About More Than Your Prescription

Glasses and contacts are important — but they are only part of what we do at your annual wellness exam. Getting your prescription right improves your day-to-day quality of life. Monitoring the health of your eyes protects your long-term vision. Both matter equally, and both happen at the same visit.

Our primary goals during every wellness exam are to determine your most accurate prescription and to screen for early signs of eye disease — including ARMD. If anything is detected, we schedule a dedicated follow-up medical exam for a more targeted approach to diagnosis, monitoring, and management. That distinction in appointment type allows us to give your eye health the focused attention it deserves.

Two Forms, Two Timelines

Dry ARMD accounts for roughly 85–90% of cases.² Drusen deposits accumulate beneath the retina, leading to gradual thinning of the retinal pigment epithelium. Progression is slow but cumulative. Wet (neovascular) ARMD is less common but far more aggressive — abnormal blood vessels leak beneath the retina, causing rapid central vision distortion. Wet ARMD requires prompt anti-VEGF treatment through a retinal specialist, and we manage care coordination from our office.

Risk Factors

Age and family history are the strongest non-modifiable risks, with CFH and ARMS2 gene variants significantly increasing susceptibility.³ Among modifiable factors, smoking carries the most substantial evidence — current smokers face two to four times the risk of non-smokers.⁴ UV exposure, a diet low in leafy greens, hypertension, and obesity also contribute to progression.

How We Monitor ARMD

Optomap with OCT Mac Screening delivers a panoramic retinal image plus a macular OCT screener in a single session — available at your first visit for less than the cost of an oil change or a vehicle inspection. When disease is identified, we step up to our Zeiss OCT for high-resolution, repeatable macular imaging to track drusen burden, atrophy, and fluid over time. Our ERG (Electroretinography) adds functional data — measuring how well your photoreceptors are actually responding to light, independent of what the structural imaging shows. This level of diagnostic depth is not commonly available in general optometry practice.

Supplementation

The AREDS and AREDS2 trials established that targeted antioxidant supplementation reduces progression risk from intermediate to advanced ARMD by approximately 25% in appropriate candidates.⁵,⁶ We carry MacuHealth (once daily; all three macular carotenoids) in-office with bundle pricing available. Preservision and Ocuvite are equally
evidence-based alternatives dosed twice daily and available at most pharmacies. The supplement you take consistently is the right one.

The Bottom Line

There is no cure for ARMD, but early detection and consistent management make a meaningful difference. If anything is found at your wellness exam, we will walk you through next steps — including whether home monitoring tools like the Amsler grid are appropriate for your individual situation. Your central vision is worth protecting proactively. Contact us to schedule your exam.

For educational purposes only. Not a substitute for individualized medical care.

Age-Related Macular Degeneration

1. Friedman DS, et al. Arch Ophthalmol. 2004;122(4):564–572. https://doi.org/10.1001/archopht.122.4.564

2. Gehrs KM, et al. Ann Med. 2006;38(7):450–471. https://doi.org/10.1080/07853890600946724

3. Klein RJ, et al. Science. 2005;308(5720):385–389. https://doi.org/10.1126/science.1109557

4. Thornton J, et al. Eye. 2005;19(9):935–944. https://doi.org/10.1038/sj.eye.6701852

5. AREDS Research Group. Arch Ophthalmol. 2001;119(10):1417–1436. https://doi.org/10.1001/archopht.119.10.1417 6. AREDS2 Research Group. JAMA. 2013;309(19):2005–2015. https://doi.org/10.1001/jama.2013.4997